Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized phase II study of weekly versus 5-day topotecan in platinum-resistant recurrent ovarian or primary peritoneal cancer
2005-001559-39Phase 2Completed
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Jun 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of topotecan in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by Charité – Universitätsmedizin Berlin. Primary endpoint: Complete and partial remission rate. Started Jun 2006; status: completed.
02
Drugs
topotecan
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2005-001559-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001559-39.